Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label, Two-step, Phase Ia/Ib Study of Tumor Targeted Prodrug RS-0139 in Patients with a Recurrent, Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Multicenter, Open Label, Two-step, Phase Ia/Ib Study of Tumor Targeted Prodrug RS-0139 in Patients with a Recurrent, Locally Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RS 0139 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.

Most Recent Events

  • 30 Oct 2024 Indication changed from Non-small-cell-lung-cancer to Solid Tumors.
  • 30 Oct 2024 Planned End Date changed from 1 Aug 2024 to 1 Dec 2025.
  • 30 Oct 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Oct 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top